VENLAFAXINE

18. Cardona X, Avila A & Castellanos P: Venlafaxine-associated hepatitis (letter). Ann Intern Med 2000; 132(5):417.
19. Chamberlain JM, Altieri MA, Futterman C et al; A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Ped Emerg Care, 1997; 13:92-94.
20. Chyka PA & Seger D: Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Clin Toxicol 1997; 35:721-736.
21. Coorey AN & Wenck DJ: Venlafaxine overdose (letter). Med J Aust 1998; 168:523.
22. Dahl B, Crouch BI & Rollins D: Death from venlafaxine overdose (Effexor(R)). J Toxicol Clin Toxicol 1996; 34:557.
23. Dallal A & Chouinard G: Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine (letter). J Clin Psychopharmacol 1998; 18:343-344.
24. Daniels RJ: Serotonin syndrome due to venlafaxine overdose. J Accid Emerg Med 1998; 15:333-334.
25. Durback LF & Scharman EJ: Seizures associated with venlafaxine overdose (abstract). J Toxicol Clin Toxicol 1996; 34:557.
26. Dursun SM, Burke JG, Nielsen F et al: SSRI-related toxic serotonin syndrome: improvement of discontinuation of treatment and propranolol. Eur Psychiatr 1997; 12:321-323.
27. Fantaskey A & Burkhart KK: A case report of venlafaxine toxicity. Clin Tox 1995; 33(4): 359-361.
28. FDA: Poison treatment drug product for over-the-counter human use; tentative final monograph. Fed Register 1985; 50:2244-2262.
29. Garber A & Gregory RJ: Benztropine in the treatment of venlafaxine- induced sweating (letter). J Clin Psychiatr 1997; 58:176-177.
30. Giang DW & McBride MC: Lorazepam versus diazepam for the treatment of status elipticus. Pediatr Neurol 1988; 4:358-361.
31. Gillman PK: Ecstasy, serotonin syndrome and the treatment of hyperpyrexia (letter). MJA 1997; 167:109-111.
32. Goldberg RJ & Huk M: Serotonin syndrome from trazodone and buspirone (letter). Psychosomatics 1992; 33:235-236.
33. Graham PM: Successful treatment of the toxic serotonin syndrome with chlorpromazine (letter). Med J Australia 1997; 166:166-167.
34. Gupta AK & Saravay SM: Venlafaxine-induced hyponatremia (letter). J Clin Psychopharmacol 1997; 17:223-225.
35. Guze BH & Baxter LR Jr: The serotonin syndrome: case responsive to propranolol (letter). J Clin Psychopharmacol 1986; 6:119-120.
36. Haskins JT, Moyer JA, Muth EA et al: DMI, WY-45,030, WY-45,881 and ciramadol inhibit locus coeruleus activity. Eur J Pharmacol 1985; 115: 139-146.
37. Herrington LF & Gorman SE: Pediatric ingestion of effexor (venlafaxine) (abstract). J Toxicol Clin Toxicol 1996; 34:558.
38. Hodgman M, Martin T, Dean B et al: Severe serotonin syndrome secondary to venlafaxine and maintenance tranylcypromine therapy (abstract). J Toxicol Clin Toxicol 1995; 33:554.
39. Hodgman MJ, Martin TG & Krenzelok EP: Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum Exp Toxicol 1997; 16:14-17.
40. Hoes MJAJM: Mirtazapine as treatment for serotonin syndrome. Pharmacopsychiatry 1996; 29:81.
41. Johnson H, Bouman WP & Lawton J: Withdrawal reaction associated with venlafaxine. Br Med J 1998; 317:787.
42. Khan A, Fabre LF & Rudolph R: Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991; 27:141-144.
43. Klamerus KJ, Maloney K, Rudolph RL et al: Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl- metabolite. J Clin Pharmacol 1992; 32:716-724.
44. Kline SS, Mauro LS, Scala-Barnett DM et al: Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharmac 1989; 8:510-514.
45. Kokan L & Dart RC: Life-threatening hypotension from venlafaxine overdose (abstract). J Toxicol Clin Toxicol 1996; 34:559.
46. Kolecki P & Miller M: Isolated venlafaxine-induced serotonin syndrome (abstract). J Toxicol Clin Toxicol 1996; 34:558.
47. Lahat E, Goldman M, Barr J et al: Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomized study. BMJ 2000; 321:83-86.
48. Leaf EV: Comment: venlafaxine overdose and seizure (letter). Ann Pharmacother 1998; 32:135-136.
49. Lessard E, Yessine MA, Hamelin BA et al: Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9(4):435-443.
50. Macbeth R & Rajagopalan M: Venlafaxine withdrawal syndrome. Aust NZ J Med 1998; 28:218.
51. Mills KC: Serotonin syndrome: a clinical update. Med Toxicol 1997; 13:763-783.
52. Muth EA, Haskins JT, Moyer JA et al: Antidepressant biochemical profile of the novel bicyclic compound WY-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986; 35:4493-4497.
53. Nimmagadda SR, Ryan DH & Atkin SL: Neuroleptic malignant syndrome after venlafaxine (letter). Lancet 2000; 354:289-290.
54. Peano C, Wahl M, Keyes N et al: Seizures and ventricular tachycardia secondary to venlafaxine and lamotrigine (abstract). J Toxicol Clin Toxicol 1996; 34:558.
55. Product Information Ativan(R), 1999, Wyeth-Ayerst Co, Philadelphia, PA
56. Product Information: Ativan(R), lorazepam. Wyeth, Philadelphia, PA, 1991.
57. Product Information: Effexor(R), venlafaxine. Wyeth-Ayerst Laboratories Inc. Philadelphia, PA, 2000.
58. Product Information: Effexor(R)XR, venlafaxine. Wyeth-Ayerst Laboratories Inc. Philadelphia, PA, 2000.
59. Riley MR (Ed): Facts and Comparisons. Facts and Comparisons, Inc, St Louis, MO, 2000.
60. Rosen P, Marek M & Borys D: Coma, hypotension, and intraventricular block in a patient with venlafaxine and clonazepam overdose (abstract). J Tox- Clin Tox 1997; 35:548.
61. Saletu B, Grunberger J, Anderer P et al: Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Br J Clin Pharmacol 1992; 33:589-601.
62. Schweizer E, Clary C, Weise C et al: An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant. Psychopharmacol Bull 1988; 24:195-197.
63. Schweizer E, Weiss C, Clary C et al: Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991; 11:233-236.
64. Scott R, Besag FMC, Neville BGR: Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomized trial. Lancet 1999; 353:623-626.
65. Setz SC, Anderson DA, Lawler et al: Acute venlafaxine overdose - a multicenter study (abstract). J Toxicol Clin Toxicol 1995; 33:496.
66. Sternbach H: The serotonin syndrome. Am J Psychiatr 1992; 149:1410-1411.
67. Thorsson B, Snook C, Thorgeirsson G et al: Survival after prolonged cardiac arrest from venlafaxine (abstract). European Association of Poisons Centres and Clinical Toxicologists. XX International Congress 2-5 May, 2000. Amsterdam, The Netherlands.
68. Troy SM, Dilea C, Martin PT et al: Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers. Curr Ther Res 1997; 58:492-503.
69. Tzallas PJ & Rynn KO: Extrapyramidal side effects secondary to venlafaxine (abstract). J Toxicol Clin Toxicol 1995; 33:518.
70. USP DI Volume I Drug information for the health care professional. 20th edition, 2000; Micromedex Inc, World Color Book Services, Taunton, MA.
71. Vale JA: Position Statement: gastric lavage. American Academy of Clinical Toxicology/European Association of Poisons Centres and Clinical Toxicologists. Clin Toxicol 1997; 35:711-719.
72. Wang CP, Howell SR, Scatina J et al: The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine (abstract). Chirality 1992; 4:84-90.
73. Weiner LA, Smythe M & Cisek J: Serotonin syndrome secondary to phenelzine- venlafaxine interaction. Pharmacother 1998; 18:399-403.
74. White CM, Gailey RA, Levin GM et al: Seizure resulting from a venlafaxine overdose. Ann Pharmacother 1997; 31:178-180.
75. Wilson R & Jenkins P: Suspected complication of treatment with venlafaxine (letter). J Clin Psychopharmacol 1997; 17:323.
76. Woo OF, Vredenburg M, Freitas P & Olson KR: Seizures after venlafaxine overdose; a case report (abstract). J Toxicol Clin Toxicol 1995; 33:549.
77. Yardley JP, Morris Husbands GE, Stack G et al: 2-Phenyl-2-(1-hydroxycyclo- alkyl)ethylamine derivatives: synthesis and antidepressant activity. J Med Chem 1990; 33:2899-2905.
78. Zajecka JM, Fawcett J & Guy C: Coexisting major depression and obsessive- compulsive disorder treated with venlafaxine (letter). J Clin Psychopharmacol 1990; 10:152-153.

13.0 AUTHOR INFORMATION

13.1 CONTRIBUTOR(S) TO THIS DOCUMENT

A. Original publication: 10/97
B. Most recent revision: 09/00
C. List of contributors:

§ 1. Jason Chu, MD

§ 2. Katherine M Hurlbut, MD

§ 3. POISINDEX(R) Editorial Staff

D. Specialty Board: PSYCHOACTIVE AND ABUSE

Refer to the POISINDEX EDITORIAL BOARD section for more information. (MG2107)

End of Document